NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
Tianjin Institute Of Pharmaceutical Research—Ne »11/09/2009 [Company watch]
Four Tianyin products included in China\'s Essential Drug List

All the drugs in the Essential Drug List will be included in China\'s basic health insurance catalog with a higher reimbursement percentage.

 
Tianyin Pharmaceutical, a manufacturer and supplier of modernized traditional Chinese medicine, has announced that it has four products included in China\'s Essential Drug List (EDL) released by the Chinese government. The four generic products are Azithromycin Dispersible Tablets, Simvastatin Tablets, Hugan Tablets and Xiao Yan Li Dan Capsules and Tablets. All the drugs in the Essential Drug List will be included in China\'s basic health insurance catalog with a higher reimbursement percentage. Meanwhile, the pricing of the Essential Drugs will be decided by the governments through public tender at the provincial level. The distribution of Essential Drugs will also be carried out through unified channels by either drug manufacturers or drug distributors. Companies winning the government tenders will have the potential to significantly increase sales while margins on generic and more commonly used drugs will see pricing control from the government. As a result of this inclusion, Tianyin\'s management expects the sales of these four drugs could potentially increase from $6.1 million in fiscal year 2009 to approximately $12 million in fiscal year 2010, which ends June 30, 2010. \"The release of China\'s essential drug list ensures that most rural citizens with comparatively low income will have access to cheap and safe medicines,\" said Dr Jiang, Chairman of Tianyin. \"We view this inclusion as an opportunity to significantly increase revenues generated from these products.\"

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.